Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 7
2003 13
2004 15
2005 12
2006 19
2007 20
2008 10
2009 15
2010 12
2011 12
2012 13
2013 23
2014 14
2015 16
2016 24
2017 29
2018 28
2019 55
2020 68
2021 79
2022 56
2023 73
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

552 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants.
Rucker JJ, Roberts C, Seynaeve M, Young AH, Suttle B, Yamamoto T, Ermakova AO, Dunbar F, Wiegand F. Rucker JJ, et al. Among authors: young ah. J Psychopharmacol. 2024 Apr 14:2698811241246857. doi: 10.1177/02698811241246857. Online ahead of print. J Psychopharmacol. 2024. PMID: 38616411
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.
Haniff ZR, Bocharova M, Mantingh T, Rucker JJ, Velayudhan L, Taylor DM, Young AH, Aarsland D, Vernon AC, Thuret S. Haniff ZR, et al. Among authors: young ah. Pharmacol Ther. 2024 Apr 6;258:108641. doi: 10.1016/j.pharmthera.2024.108641. Online ahead of print. Pharmacol Ther. 2024. PMID: 38583670 Review.
Efficacy and safety of established and off-label ADHD drug therapies for cognitive impairment or attention-deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force.
Miskowiak KW, Obel ZK, Gugliemo R, Bonnin CDM, Bowie CR, Balanzá-Martínez V, Burdick KE, Carvalho AF, Dols A, Douglas K, Gallagher P, Kessing LV, Lafer B, Lewandowski KE, López-Jaramillo C, Martinez-Aran A, McIntyre RS, Porter RJ, Purdon SE, Schaffer A, Stokes PRA, Sumiyoshi T, Torres IJ, Van Rheenen TE, Yatham LN, Young AH, Vieta E, Hasler G. Miskowiak KW, et al. Among authors: young ah. Bipolar Disord. 2024 Mar 3. doi: 10.1111/bdi.13414. Online ahead of print. Bipolar Disord. 2024. PMID: 38433530 Review.
A New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study.
Pelgrim TAD, Philipsen A, Young AH, Juruena M, Jimenez E, Vieta E, Jukić M, Van der Eycken E, Heilbronner U, Moldovan R, Kas MJH, Jagesar RR, Nöthen MM, Hoffmann P, Shomron N, Kilarski LL, van Amelsvoort T, Campforts B, The Psy-PGx Consortium, van Westrhenen R. Pelgrim TAD, et al. Among authors: young ah. Pharmaceuticals (Basel). 2024 Jan 23;17(2):151. doi: 10.3390/ph17020151. Pharmaceuticals (Basel). 2024. PMID: 38399366 Free PMC article.
552 results